Copyright © Inderes 2011 - present. All rights reserved.

Scibase Holding

0.22 SEK

+2.33 %

Less than 1K followers

SCIB

First North Stockholm

Medical Equipment & Services

Health Care

+2.33 %
-23.48 %
-23.92 %
-17.50 %
-29.41 %
-30.16 %
-92.09 %
-92.59 %
-99.06 %

SciBase Holding is a global medical technology group specialized in diagnostics and prevention in dermatology. The company develops, produces and commercializes Nevisense, a patient-centered platform that combines AI (artificial intelligence) with EIS technology to enable early detection and intervention of skin cancer and other skin diseases. Nevisense is based on over 20 years of research at Karolinska Institutet, the headquarters are in Stockholm.

Read more
Market cap
224.96M SEK
Turnover
77.53K SEK
Revenue
29.71M
EBIT %
-226.09 %
P/E
-
Dividend yield-%
-
Latest research

Latest analysis report

Released: 2024-12-02

Latest extensive report

Released: 2024-02-01

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
24/2
2026

Annual report '25

7/5
2026

Interim report Q1'26

19/5
2026

General meeting '26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Now, apparently, a solution is being sought in connection with a share issue for this difficult capital structure due to TO2 warrants. Warrants are being converted into shares here, so that two warrants are exchanged for one share Inderes The Board of Directors in SciBase resolves...
11/7/2025, 8:09 AM
by Antti Luiro
5
Interesting company, and with the increasing prevalence of melanoma, the market should grow. I personally held a small position in this, but those warrants seem to prevent a larger price increase. In addition, revenue growth has been so slow that a new share issue (and more warrants...
5/14/2025, 10:31 AM
3
Unfortunately, the coverage ended a while ago, so we don’t have fresh comments available. If one considers the share price formation, this point about the termination of coverage is very essential to keep in mind: We highlight that the high number of TO2 warrants (strike price SEK...
5/14/2025, 10:12 AM
by Antti Luiro
3
Hi, is Scibase still under Inderes’ coverage? It would be nice to hear updated views from the analyst and others following the company. Q1 results came out yesterday. Sales in the US seem to have grown significantly. The share price has fluctuated between 0.3 and 0.5 since last summer...
5/14/2025, 9:26 AM
by JJ
2
SciBase’s Q3 video is now also out Inderes SciBase Q3’24: Waiting for the clear waters - Inderes Time: 14.11.2024 klo 14.09 SciBase kept building its commercial momentum in the US, where it achieved strong revenue growth in Q3. Yet, the major news of the day was the large capital...
11/14/2024, 12:23 PM
by Mikael Maijala
2
Here is Luiro’s latest company report on SciBase. SciBase grew strongly in the US during Q3, but the day’s biggest news was the large “capital raise,” which is expected to support the turn to positive cash flow. SciBase kept building its commercial momentum in the US where it achieved...
11/13/2024, 9:50 AM
by Sijoittaja-alokas
2
Thanks for the insights. Can more experienced investors estimate how common it is for the option exercise period to be set so far out, all the way to spring 2029? It feels like a very long timeframe. This is indeed a big hindrance to the share price increase, especially since such...
5/14/2025, 11:55 AM
by JJ
1
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.